DOCSLIB.ORG

Supplementary Table 2 - in Silico Reconstruction of the Metabolic Pathways of S

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Supplementary Table 2 - in Silico Reconstruction of the Metabolic Pathways of S Supplementary Table 2 - In silico reconstruction of the metabolic pathways of S. amnii , S. moniliformis , L. buccalis and S. termiditis Metabolic reconstruction assignments, FOUND or NF (Not Found) status (columns D, E, F and G), were performed using ASGARD, EC number Enzyme/pathway name (KEGG) S. amnii S. moniliformis L. buccalis S. termiditis 1 >Glycolysis / Gluconeogenesis 00010 2 1.1.1.1 Alcohol dehydrogenase. FOUND FOUND FOUND FOUND 3 1.1.1.2 Alcohol dehydrogenase (NADP(+)). NF NF FOUND NF 4 1.1.1.27 L-lactate dehydrogenase. FOUND FOUND NF FOUND 5 1.1.2.7 Methanol dehydrogenase (cytochrome c). NF NF NF NF 6 1.1.2.8 Alcohol dehydrogenase (cytochrome c). NF NF NF NF 7 1.2.1.12 Glyceraldehyde-3-phosphate dehydrogenase (phosphorylating).FOUND FOUND FOUND FOUND 8 1.2.1.3 Aldehyde dehydrogenase (NAD(+)). NF NF FOUND FOUND 9 1.2.1.5 Aldehyde dehydrogenase (NAD(P)(+)). NF NF NF NF 10 1.2.1.59 Glyceraldehyde-3-phosphate dehydrogenase (NAD(P)(+))NF (phosphorylating).NF NF NF 11 1.2.1.9 Glyceraldehyde-3-phosphate dehydrogenase (NADP(+)).FOUND FOUND FOUND FOUND 12 1.2.4.1 Pyruvate dehydrogenase (acetyl-transferring). FOUND FOUND FOUND FOUND 13 1.2.7.1 Pyruvate synthase. NF NF NF NF 14 1.2.7.5 Aldehyde ferredoxin oxidoreductase. NF NF NF NF 15 1.2.7.6 Glyceraldehyde-3-phosphate dehydrogenase (ferredoxin).NF NF NF NF 16 1.8.1.4 Dihydrolipoyl dehydrogenase. FOUND FOUND FOUND FOUND 17 2.3.1.12 Dihydrolipoyllysine-residue acetyltransferase. FOUND FOUND FOUND FOUND 18 2.7.1.1 Hexokinase. NF NF NF NF 19 2.7.1.11 6-phosphofructokinase. FOUND FOUND FOUND FOUND 20 2.7.1.146 ADP-specific phosphofructokinase. NF NF NF NF 21 2.7.1.147 ADP-specific glucokinase. NF NF NF NF 22 2.7.1.2 Glucokinase. FOUND FOUND FOUND FOUND 23 2.7.1.40 Pyruvate kinase. FOUND FOUND FOUND FOUND 24 2.7.1.41 Glucose-1-phosphate phosphodismutase. NF NF NF NF 25 2.7.1.63 Polyphosphate--glucose phosphotransferase. NF NF NF NF 26 2.7.1.69 Protein-N(pi)-phosphohistidine--sugar phosphotransferase.FOUND FOUND FOUND FOUND 27 2.7.2.3 Phosphoglycerate kinase. FOUND FOUND FOUND FOUND 28 3.1.3.10 Glucose-1-phosphatase. NF NF NF NF 29 3.1.3.11 Fructose-bisphosphatase. NF NF NF FOUND 30 3.1.3.13 Bisphosphoglycerate phosphatase. NF NF NF NF 31 3.1.3.9 Glucose-6-phosphatase. NF NF NF NF 32 3.2.1.86 6-phospho-beta-glucosidase. NF NF NF NF 33 4.1.1.1 Pyruvate decarboxylase. NF NF NF NF 34 4.1.1.32 Phosphoenolpyruvate carboxykinase (GTP). NF NF NF NF 35 4.1.1.49 Phosphoenolpyruvate carboxykinase (ATP). NF NF FOUND FOUND 36 4.1.2.13 Fructose-bisphosphate aldolase. FOUND FOUND FOUND FOUND 37 4.2.1.11 Phosphopyruvate hydratase. FOUND FOUND FOUND FOUND 38 5.1.3.15 Glucose-6-phosphate 1-epimerase. NF NF NF NF 39 5.1.3.3 Aldose 1-epimerase. NF FOUND NF FOUND 40 5.3.1.1 Triose-phosphate isomerase. FOUND FOUND FOUND FOUND 41 5.3.1.9 Glucose-6-phosphate isomerase. FOUND FOUND FOUND FOUND 42 5.4.2.1 Phosphoglycerate mutase. FOUND FOUND FOUND FOUND 43 5.4.2.2 Phosphoglucomutase. FOUND FOUND FOUND FOUND 44 5.4.2.4 Bisphosphoglycerate mutase. NF NF NF NF 45 6.2.1.1 Acetate--CoA ligase. NF NF NF NF 46 6.2.1.13 Acetate--CoA ligase (ADP-forming). NF NF NF NF 47 >Citrate cycle (TCA cycle) 00020 48 1.1.1.37 Malate dehydrogenase. NF NF NF NF 49 1.1.1.41 Isocitrate dehydrogenase (NAD(+)). NF NF FOUND FOUND 50 1.1.1.42 Isocitrate dehydrogenase (NADP(+)). NF NF FOUND FOUND 51 1.2.4.1 Pyruvate dehydrogenase (acetyl-transferring). FOUND FOUND FOUND FOUND 52 1.2.4.2 Oxoglutarate dehydrogenase (succinyl-transferring).NF NF NF NF 53 1.2.7.1 Pyruvate synthase. NF NF NF NF 54 1.2.7.3 2-oxoglutarate synthase. NF NF NF NF 55 1.3.5.1 Succinate dehydrogenase (ubiquinone). NF NF NF NF 56 1.3.99.1 Succinate dehydrogenase. NF NF NF NF 57 1.8.1.4 Dihydrolipoyl dehydrogenase. FOUND FOUND FOUND FOUND 58 2.3.1.12 Dihydrolipoyllysine-residue acetyltransferase. FOUND FOUND FOUND FOUND 59 2.3.1.61 Dihydrolipoyllysine-residue succinyltransferase. FOUND NF FOUND NF 60 2.3.3.1 Citrate (Si)-synthase. NF NF FOUND FOUND 61 2.3.3.8 ATP citrate synthase. NF NF NF NF 62 4.1.1.32 Phosphoenolpyruvate carboxykinase (GTP). NF NF NF NF 63 4.1.1.49 Phosphoenolpyruvate carboxykinase (ATP). NF NF FOUND FOUND 64 4.1.3.6 Citrate (pro-3S)-lyase. NF NF NF NF 65 4.2.1.2 Fumarate hydratase. NF NF NF FOUND 66 4.2.1.3 Aconitate hydratase. NF NF FOUND NF 67 6.2.1.4 Succinate--CoA ligase (GDP-forming). NF NF NF NF 68 6.2.1.5 Succinate--CoA ligase (ADP-forming). NF NF NF NF 69 6.4.1.1 Pyruvate carboxylase. NF NF NF NF 70 >Pentose phosphate pathway 00030 71 1.1.1.215 Gluconate 2-dehydrogenase. NF NF NF NF 72 1.1.1.43 Phosphogluconate 2-dehydrogenase. NF NF NF NF 73 1.1.1.44 Phosphogluconate dehydrogenase (decarboxylating).NF NF NF NF 74 1.1.1.47 Glucose 1-dehydrogenase. NF NF NF NF 75 1.1.1.49 Glucose-6-phosphate dehydrogenase. NF NF NF NF 76 1.1.3.4 Glucose oxidase. NF NF NF NF 77 1.1.3.5 Hexose oxidase. NF NF NF NF 78 1.1.5.2 Quinoprotein glucose dehydrogenase. NF NF NF NF 79 1.1.99.10 Glucose dehydrogenase (acceptor). NF NF NF NF 80 1.1.99.3 Gluconate 2-dehydrogenase (acceptor). NF NF NF NF 81 1.2.7.5 Aldehyde ferredoxin oxidoreductase. NF NF NF NF 82 2.2.1.1 Transketolase. FOUND FOUND FOUND FOUND 83 2.2.1.2 Transaldolase. FOUND NF FOUND FOUND 84 2.7.1.- Phosphotransferases with an alcohol group as acceptor.FOUND FOUND FOUND FOUND 85 2.7.1.11 6-phosphofructokinase. FOUND FOUND FOUND FOUND 86 2.7.1.12 Gluconokinase. NF NF NF NF 87 2.7.1.13 Dehydrogluconokinase. NF NF NF NF 88 2.7.1.15 Ribokinase. FOUND FOUND FOUND FOUND 89 2.7.1.45 2-dehydro-3-deoxygluconokinase. FOUND FOUND NF FOUND 90 2.7.4.23 Ribose 1,5-bisphosphate phosphokinase. NF NF NF NF 91 2.7.6.1 Ribose-phosphate diphosphokinase. FOUND FOUND FOUND FOUND 92 3.1.1.17 Gluconolactonase. NF NF NF NF 93 3.1.1.31 6-phosphogluconolactonase. NF NF NF NF 94 3.1.3.11 Fructose-bisphosphatase. NF NF NF FOUND 95 4.1.2.- Aldehyde-lyases. FOUND FOUND FOUND FOUND 96 4.1.2.13 Fructose-bisphosphate aldolase. FOUND FOUND FOUND FOUND 97 4.1.2.14 2-dehydro-3-deoxy-phosphogluconate aldolase. FOUND FOUND NF FOUND 98 4.1.2.4 Deoxyribose-phosphate aldolase. FOUND FOUND FOUND FOUND 99 4.1.2.9 Phosphoketolase. NF NF NF NF 100 4.2.1.12 Phosphogluconate dehydratase. NF NF NF NF 101 4.2.1.39 Gluconate dehydratase. NF NF NF NF 102 4.3.1.9 Glucosaminate ammonia-lyase. NF NF NF NF 103 5.1.3.1 Ribulose-phosphate 3-epimerase. FOUND FOUND FOUND FOUND 104 5.3.1.6 Ribose-5-phosphate isomerase. FOUND FOUND FOUND FOUND 105 5.3.1.9 Glucose-6-phosphate isomerase. FOUND FOUND FOUND FOUND 106 5.4.2.2 Phosphoglucomutase. FOUND FOUND FOUND FOUND 107 5.4.2.7 Phosphopentomutase. FOUND NF FOUND FOUND 108 >Pentose and glucuronate interconversions 00040 109 1.1.1.10 L-xylulose reductase. NF NF NF NF 110 1.1.1.11 D-arabinitol 4-dehydrogenase. NF NF NF NF 111 1.1.1.12 L-arabinitol 4-dehydrogenase. NF NF NF NF 112 1.1.1.125 2-deoxy-D-gluconate 3-dehydrogenase. NF FOUND NF FOUND 113 1.1.1.127 2-dehydro-3-deoxy-D-gluconate 5-dehydrogenase. NF NF NF NF 114 1.1.1.13 L-arabinitol 2-dehydrogenase. NF NF NF NF 115 1.1.1.130 3-dehydro-L-gulonate 2-dehydrogenase. NF NF NF NF 116 1.1.1.137 Ribitol-5-phosphate 2-dehydrogenase. NF NF NF NF 117 1.1.1.15 D-iditol 2-dehydrogenase. NF NF NF NF 118 1.1.1.175 D-xylose 1-dehydrogenase. NF NF NF NF 119 1.1.1.179 D-xylose 1-dehydrogenase (NADP(+)). NF NF NF NF 120 1.1.1.19 Glucuronate reductase. NF NF NF NF 121 1.1.1.21 Aldehyde reductase. NF NF FOUND FOUND 122 1.1.1.22 UDP-glucose 6-dehydrogenase. NF NF NF FOUND 123 1.1.1.45 L-gulonate 3-dehydrogenase. NF NF NF NF 124 1.1.1.56 Ribitol 2-dehydrogenase. NF NF NF NF 125 1.1.1.57 Fructuronate reductase. FOUND NF NF NF 126 1.1.1.58 Tagaturonate reductase. NF NF NF FOUND 127 1.1.1.9 D-xylulose reductase. NF NF NF NF 128 1.1.2.2 Mannitol dehydrogenase (cytochrome). NF NF NF NF 129 1.2.1.3 Aldehyde dehydrogenase (NAD(+)). NF NF FOUND FOUND 130 2.4.1.17 Glucuronosyltransferase. NF NF NF NF 131 2.7.1.16 Ribulokinase.
Load more

Recommended publications
  • Causes and Evaluation of Mildly Elevated Liver Transaminase Levels ROBERT C
    Causes and Evaluation of Mildly Elevated Liver Transaminase Levels ROBERT C. OH, LTC, MC, USA, and THOMAS R. HUSTEAD, LTC, MC, USA Tripler Army Medical Center Family Medicine Residency Program, Honolulu, Hawaii Mild elevations in levels of the liver enzymes alanine transaminase and aspartate transaminase are commonly dis- covered in asymptomatic patients in primary care. Evidence to guide the diagnostic workup is limited. If the history and physical examination do not suggest a cause, a stepwise evaluation should be initiated based on the prevalence of diseases that cause mild elevations in transaminase levels. The most common cause is nonalcoholic fatty liver disease, which can affect up to 30 percent of the population. Other common causes include alcoholic liver disease, medication- associated liver injury, viral hepatitis (hepatitis B and C), and hemochromatosis. Less common causes include α1-antitrypsin deficiency, autoimmune hepatitis, and Wilson disease. Extrahepatic conditions (e.g., thyroid disorders, celiac disease, hemolysis, muscle disorders) can also cause elevated liver transaminase levels. Initial testing should include a fasting lipid profile; measurement of glucose, serum iron, and ferritin; total iron-binding capacity; and hepa- titis B surface antigen and hepatitis C virus antibody testing. If test results are normal, a trial of lifestyle modification with observation or further testing for less common causes is appropriate. Additional testing may include ultrasonog- raphy; measurement of α1-antitrypsin and ceruloplasmin; serum protein electrophoresis; and antinuclear antibody, smooth muscle antibody, and liver/kidney microsomal antibody type 1 testing. Referral for further evaluation and possible liver biopsy is recommended if transaminase levels remain elevated for six months or more.
    [Show full text]
  • Structural Insights Into Histone Modifying Enzymes
    Wayne State University Wayne State University Theses January 2019 Structural Insights Into Histone Modifying Enzymes Shruti Amle Wayne State University, [email protected] Follow this and additional works at: https://digitalcommons.wayne.edu/oa_theses Part of the Biochemistry Commons, and the Molecular Biology Commons Recommended Citation Amle, Shruti, "Structural Insights Into Histone Modifying Enzymes" (2019). Wayne State University Theses. 693. https://digitalcommons.wayne.edu/oa_theses/693 This Open Access Embargo is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in Wayne State University Theses by an authorized administrator of DigitalCommons@WayneState. STRUCTURAL INSIGHTS INTO HISTONE MODIFYING ENZYMES by SHRUTI AMLE THESIS Submitted to the Graduate School of Wayne State University, Detroit, Michigan in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE 2019 MAJOR: BIOCHEMISTRY AND MOLECULAR BIOLOGY Approved By: _________________________________________ Advisor Date _________________________________________ _________________________________________ _________________________________________ i ACKNOWLEDGEMENTS Writing this thesis has been extremely captivating and gratifying. I take this opportunity to express my deep and sincere acknowledgements to the number of people for extending their generous support and unstinted help during my entire study. Firstly, I would like to express my respectful regards and deep sense of gratitude to my advisor, Dr. Zhe Yang. I am extremely honored to study and work under his guidance. His vision, ideals, timely motivation and immense knowledge had a deep influence on my entire journey of this career. Without his understanding and support, it would not have been possible to complete this research successfully. I also owe my special thanks to my committee members: Dr.
    [Show full text]
  • Annual Conference Abstracts
    ANNUAL CONFERENCE 14-17 April 2014 Arena and Convention Centre, Liverpool ABSTRACTS SGM ANNUAL CONFERENCE APRIL 2014 ABSTRACTS (LI00Mo1210) – SGM Prize Medal Lecture (LI00Tu1210) – Marjory Stephenson Climate Change, Oceans, and Infectious Disease Prize Lecture Dr. Rita R. Colwell Understanding the basis of antibiotic resistance University of Maryland, College Park, MD, USA as a platform for early drug discovery During the mid-1980s, satellite sensors were developed to monitor Laura JV Piddock land and oceans for purposes of understanding climate, weather, School of Immunity & Infection and Institute of Microbiology and and vegetation distribution and seasonal variations. Subsequently Infection, University of Birmingham, UK inter-relationships of the environment and infectious diseases Antibiotic resistant bacteria are one of the greatest threats to human were investigated, both qualitatively and quantitatively, with health. Resistance can be mediated by numerous mechanisms documentation of the seasonality of diseases, notably malaria including mutations conferring changes to the genes encoding the and cholera by epidemiologists. The new research revealed a very target proteins as well as RND efflux pumps, which confer innate close interaction of the environment and many other infectious multi-drug resistance (MDR) to bacteria. The production of efflux diseases. With satellite sensors, these relationships were pumps can be increased, usually due to mutations in regulatory quantified and comparatively analyzed. More recent studies of genes, and this confers resistance to antibiotics that are often used epidemic diseases have provided models, both retrospective and to treat infections by Gram negative bacteria. RND MDR efflux prospective, for understanding and predicting disease epidemics, systems not only confer antibiotic resistance, but altered expression notably vector borne diseases.
    [Show full text]
  • Neuroleptic Malignant Syndrome: Another Medical Cause of Acute Abdomen T.C.N
    Postgraduate Medical Journal (1989) 65, 653 - 655 Postgrad Med J: first published as 10.1136/pgmj.65.767.653 on 1 September 1989. Downloaded from Missed Diagnosis Neuroleptic malignant syndrome: another medical cause of acute abdomen T.C.N. Lo, M.R. Unwin and I.W. Dymock Department ofMedicine, Stepping Hill Hospital, Stockport, UK. Summary: We present a patient with neuroleptic malignant syndrome and intestinal pseudo- obstruction misdiagnosed as being secondary to septicaemia. The management of the patient is discussed with emphasis on the role of creatine kinase and liver function tests. Introduction Neuroleptic malignant syndrome (NMS) is an occas- (92% neutrophils), serum sodium 130 mmol/l, potas- ional but potentially lethal idiosyncratic complication sium 5.1 mmol/l, urea 8.8 mmol/l, creatinine 79 1tmol/ ofneuroleptic drugs.'"2 By February 1989 the Commit- 1, bilirubin 15 Amol/l, alanine transaminase 837 IU/i tee on Safety of Medicines had received reports of 99 (normal 7-45), aspartate transaminase 392 IU/l (nor- cases. (Committee on Safety of Medicines, personal mal 9-41), gamma glutamyl transferase 15 IU/I (nor- Protected by copyright. Communication). It is thought that the condition is mal <65), alkaline phosphatase 62 IU/I (normal underdiagnosed.34 We report on a case of NMS of 35-125). Serial electrocardiograms showed sinus which the presenting features and therapeutic comp- tachycardia with no acute change. Abdominal X-ray lications occurring during the course of the illness revealed marked gaseous distension ofsmall and large served to further our knowledge in this condition. bowels with multiple fluid levels seen on decubitus films.
    [Show full text]
  • Supplementary Materials
    1 Supplementary Materials: Supplemental Figure 1. Gene expression profiles of kidneys in the Fcgr2b-/- and Fcgr2b-/-. Stinggt/gt mice. (A) A heat map of microarray data show the genes that significantly changed up to 2 fold compared between Fcgr2b-/- and Fcgr2b-/-. Stinggt/gt mice (N=4 mice per group; p<0.05). Data show in log2 (sample/wild-type). 2 Supplemental Figure 2. Sting signaling is essential for immuno-phenotypes of the Fcgr2b-/-lupus mice. (A-C) Flow cytometry analysis of splenocytes isolated from wild-type, Fcgr2b-/- and Fcgr2b-/-. Stinggt/gt mice at the age of 6-7 months (N= 13-14 per group). Data shown in the percentage of (A) CD4+ ICOS+ cells, (B) B220+ I-Ab+ cells and (C) CD138+ cells. Data show as mean ± SEM (*p < 0.05, **p<0.01 and ***p<0.001). 3 Supplemental Figure 3. Phenotypes of Sting activated dendritic cells. (A) Representative of western blot analysis from immunoprecipitation with Sting of Fcgr2b-/- mice (N= 4). The band was shown in STING protein of activated BMDC with DMXAA at 0, 3 and 6 hr. and phosphorylation of STING at Ser357. (B) Mass spectra of phosphorylation of STING at Ser357 of activated BMDC from Fcgr2b-/- mice after stimulated with DMXAA for 3 hour and followed by immunoprecipitation with STING. (C) Sting-activated BMDC were co-cultured with LYN inhibitor PP2 and analyzed by flow cytometry, which showed the mean fluorescence intensity (MFI) of IAb expressing DC (N = 3 mice per group). 4 Supplemental Table 1. Lists of up and down of regulated proteins Accession No.
    [Show full text]
  • Structural Properties of the Nickel Ions in Urease: Novel Insights Into the Catalytic and Inhibition Mechanisms
    Coordination Chemistry Reviews 190–192 (1999) 331–355 www.elsevier.com/locate/ccr Structural properties of the nickel ions in urease: novel insights into the catalytic and inhibition mechanisms Stefano Ciurli a,*, Stefano Benini b, Wojciech R. Rypniewski b, Keith S. Wilson c, Silvia Miletti a, Stefano Mangani d a Institute of Agricultural Chemistry, Uni6ersity of Bologna, Viale Berti Pichat 10, I-40127 Bologna, Italy b European Molecular Biology Laboratory, c/o DESY, Notkestraße 85, D-22603 Hamburg, Germany c Department of Chemistry, Uni6ersity of York, Heslington, York YO15DD, UK d Department of Chemistry, Uni6ersity of Siena, Pian dei Mantellini 44, I-53100 Siena, Italy Accepted 13 March 1999 Contents Abstract.................................................... 331 1. Biological background ......................................... 332 2. Spectroscopic investigations of the urease active site structure .................. 333 3. Crystallographic studies of the native enzyme ............................ 334 4. Crystallographic studies of urease mutants.............................. 341 5. Crystallographic studies of urease–inhibitor complexes ...................... 345 6. Crystallographic study of a transition state analogue bound to urease.............. 348 7. A novel proposal for the urease mechanism ............................. 350 References .................................................. 353 Abstract This work provides a comprehensive critical summary of urease spectroscopy, crystallogra- phy, inhibitor binding, and site-directed
    [Show full text]
  • Supplementary Table S1. Table 1. List of Bacterial Strains Used in This Study Suppl
    Supplementary Material Supplementary Tables: Supplementary Table S1. Table 1. List of bacterial strains used in this study Supplementary Table S2. List of plasmids used in this study Supplementary Table 3. List of primers used for mutagenesis of P. intermedia Supplementary Table 4. List of primers used for qRT-PCR analysis in P. intermedia Supplementary Table 5. List of the most highly upregulated genes in P. intermedia OxyR mutant Supplementary Table 6. List of the most highly downregulated genes in P. intermedia OxyR mutant Supplementary Table 7. List of the most highly upregulated genes in P. intermedia grown in iron-deplete conditions Supplementary Table 8. List of the most highly downregulated genes in P. intermedia grown in iron-deplete conditions Supplementary Figures: Supplementary Figure 1. Comparison of the genomic loci encoding OxyR in Prevotella species. Supplementary Figure 2. Distribution of SOD and glutathione peroxidase genes within the genus Prevotella. Supplementary Table S1. Bacterial strains Strain Description Source or reference P. intermedia V3147 Wild type OMA14 isolated from the (1) periodontal pocket of a Japanese patient with periodontitis V3203 OMA14 PIOMA14_I_0073(oxyR)::ermF This study E. coli XL-1 Blue Host strain for cloning Stratagene S17-1 RP-4-2-Tc::Mu aph::Tn7 recA, Smr (2) 1 Supplementary Table S2. Plasmids Plasmid Relevant property Source or reference pUC118 Takara pBSSK pNDR-Dual Clonetech pTCB Apr Tcr, E. coli-Bacteroides shuttle vector (3) plasmid pKD954 Contains the Porpyromonas gulae catalase (4)
    [Show full text]
  • 2016 Joint Meeting Program
    April 15 – 17, 2016 Fairmont Chicago Millennium Park • Chicago, Illinois The AAP/ASCI/APSA conference is jointly provided by Boston University School of Medicine and AAP/ASCI/APSA. Meeting Program and Abstracts www.jointmeeting.org www.jointmeeting.org Special Events at the 2016 AAP/ASCI/APSA Joint Meeting Friday, April 15 Saturday, April 16 ASCI President’s Reception ASCI Food and Science Evening 6:15 – 7:15 p.m. 6:30 – 9:00 p.m. Gold Room The Mid-America Club, Aon Center ASCI Dinner & New Member AAP Member Banquet Induction Ceremony (Ticketed guests only) (Ticketed guests only) 7:00 – 10:00 p.m. 7:30 – 9:45 p.m. Imperial Ballroom, Level B2 Rouge, Lobby Level How to Solve a Scientific Puzzle: Speaker: Clara D. Bloomfield, MD Clues from Stockholm and Broadway The Ohio State University Comprehensive Cancer Center Speaker: Joe Goldstein, MD APSA Welcome Reception & University of Texas Southwestern Medical Center at Dallas Presidential Address APSA Dinner (Ticketed guests only) 9:00 p.m. – Midnight Signature Room, 360 Chicago, 7:30 – 9:00 p.m. John Hancock Center (off-site) Rouge, Lobby Level Speaker: Daniel DelloStritto, APSA President Finding One’s Scientific Niche: Musings from a Clinical Neuroscientist Speaker: Helen Mayberg, MD, Emory University Dessert Reception (open to all attendees) 10:00 p.m. – Midnight Imperial Foyer, Level B2 Sunday, April 17 APSA Future of Medicine and www.jointmeeting.org Residency Luncheon Noon – 2:00 p.m. Rouge, Lobby Level 2 www.jointmeeting.org Program Contents General Program Information 4 Continuing Medical Education Information 5 Faculty and Speaker Disclosures 7 Scientific Program Schedule 9 Speaker Biographies 16 Call for Nominations: 2017 Harrington Prize for Innovation in Medicine 26 AAP/ASCI/APSA Joint Meeting Faculty 27 Award Recipients 29 Call for Nominations: 2017 Harrington Scholar-Innovator Award 31 Call for Nominations: George M.
    [Show full text]
  • Progress Toward Understanding the Contribution of Alkali Generation in Dental Biofilms to Inhibition of Dental Caries
    International Journal of Oral Science (2012) 4, 135–140 ß 2012 WCSS. All rights reserved 1674-2818/12 www.nature.com/ijos REVIEW Progress toward understanding the contribution of alkali generation in dental biofilms to inhibition of dental caries Ya-Ling Liu1, Marcelle Nascimento2 and Robert A Burne1 Alkali production by oral bacteria is believed to have a major impact on oral microbial ecology and to be inibitory to the initiation and progression of dental caries. A substantial body of evidence is beginning to accumulate that indicates the modulation of the alkalinogenic potential of dental biofilms may be a promising strategy for caries control. This brief review highlights recent progress toward understanding molecular genetic and physiologic aspects of important alkali-generating pathways in oral bacteria, and the role of alkali production in the ecology of dental biofilms in health and disease. International Journal of Oral Science (2012) 4, 135–140; doi:10.1038/ijos.2012.54; published online 21 September 2012 Keywords: arginine; biofilm; dental caries; microbial ecology; urea INTRODUCTION via the arginine deiminase system (ADS).15–18 Urea is provided con- Dental biofilms, the microbial communities that colonize the surfaces tinuously in salivary secretions and gingival exudates at concentra- of the teeth, exist in a dynamic equilibrium with host defenses and are tions roughly equivalent to those in serum, which range from about 3 generally compatible with the integrity of the tissues they colonize.1–4 to10 mmol?L21 in healthy humans. Urea is rapidly converted to A strong correlation is evident between the compositional and meta- ammonia and CO2 by bacterial ureases (Figure 1), which are produced bolic changes of the dental biofilms and the transition from oral health by a small subset of oral bacteria that includes Streptococcus salivarius, 2,5 to disease states, including dental caries and periodontal disease.
    [Show full text]
  • Quantum Chemical Cluster Modeling of Enzymatic Reactions Rong-Zhen
    Quantum Chemical Cluster Modeling of Enzymatic Reactions Rong-Zhen Liao 1 Rong-Zhen Liao, Stockholm, 2010 ISBN 978-91-7447-129-8 Printed in Sweden by US-AB, Stockholm 2010 Distributor: Department of Organic Chemistry, Stockholm University 2 3 4 Abstract The Quantum chemical cluster approach has been shown to be quite powerful and efficient in the modeling of enzyme active sites and reaction mechanisms. In this thesis, the reaction mechanisms of several enzymes have been investigated using the hybrid density functional B3LYP. The enzymes studied include four dinuclear zinc enzymes, namely dihydroorotase, N-acyl-homoserine lactone hydrolase, RNase Z, and human renal dipeptidase, two trinuclear zinc enzymes, namely phospholipase C and nuclease P1, two tungstoenzymes, namely formaldehyde ferredoxin oxidoreductase and acetylene hydratase, aspartate α-decarboxylase, and mycolic acid cyclopropane synthase. The potential energy profiles for various mechanistic scenarios have been calculated and analyzed. The role of the metal ions as well as important active site residues has been discussed. In the cluster approach, the effects of the parts of the enzyme that are not explicitly included in the model are taken into account using implicit solvation methods. With aspartate α-decarboxylase as an example, systematic evaluation of the solvation effects with the increase of the model size has been performed. At a model size of 150-200 atoms, the solvation effects almost vanish and the choice of the dielectric constant becomes rather insignificant. For all six zinc-dependent enzymes studied, the di-zinc bridging hydroxide has been shown to be capable of performing nucleophilic attack on the substrate. In addition, one, two, or even all three zinc ions participate in the stabilization of the negative charge in the transition states and intermediates, thereby lowering the barriers.
    [Show full text]
  • Expression of Genes Encoding Acetyl-Coa Carboxylase, Biotin Synthase, and Acetyl-Coa Generating Enzymes in Arabidopsis Thaliana Jinshan Ke Iowa State University
    Iowa State University Capstones, Theses and Retrospective Theses and Dissertations Dissertations 1997 Expression of genes encoding acetyl-CoA carboxylase, biotin synthase, and acetyl-CoA generating enzymes in Arabidopsis thaliana Jinshan Ke Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/rtd Part of the Botany Commons, and the Molecular Biology Commons Recommended Citation Ke, Jinshan, "Expression of genes encoding acetyl-CoA carboxylase, biotin synthase, and acetyl-CoA generating enzymes in Arabidopsis thaliana " (1997). Retrospective Theses and Dissertations. 11996. https://lib.dr.iastate.edu/rtd/11996 This Dissertation is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. INFORMATION TO USERS This manuscript has been reproduced from the microfilm master. UMI films the text directly fi"om the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter fece, while others may be from any type of computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely aflfect reproduction. In the unlikely event that the author did not send UMI a complete manuscript and there are missing pages, these will be noted. Also, if unauthorized copyright material had to be removed, a note will indicate the deletion.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]